Skip to main content
SpringerLink
Log in

Aldesleukin

Interleukin-2 (IL-2), IL-2 (Chiron), Macrolin, Proleukin®, Recombinant IL-2 (Chiron), T cell growth factor

  • Section 2: Depatitis C
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sarna G, Machleder H, Collins J, et al. A comparative study of intravenous versus intralymphatic interleukin-2, with assessment of effects of interleukin-2 on both peripheral blood and thoracic-duct lymph. J Immunother 1994 Feb; 15: 140–6

    Article  CAS  Google Scholar 

  2. Kintzel PE, Calis KA. Recombinant interleukin-2: a biological response modifier. Clin Pharm 1991 Feb; 10: 110–28

    PubMed  CAS  Google Scholar 

  3. Konrad MW, Hemstreet G, Hersh EM, et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res 1990 Apr 1; 50: 2009–17

    PubMed  CAS  Google Scholar 

  4. Bocci V, Carraro F, Zeuli M, et al. The lymphatic route. VIII. Distribution and plasma clearance of recombinant human interleukin-2 after SC administration with albumin in patients. Biotherapy 1993 Jan; 6: 73–7

    Article  PubMed  CAS  Google Scholar 

  5. Jeal W, Goa KL. Aldesleukin (recombinant interleukin-2): a review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma. BioDrugs 1997 Apr; 7: 285–317

    Article  PubMed  CAS  Google Scholar 

  6. Davey Jr RT, Chaitt DG, Piscitelli SC, et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997 Apr; 175: 781–9

    Article  PubMed  CAS  Google Scholar 

  7. Von der Maase H, Geertsen P, Thatcher N, et al. Recombinant interleukin-2 in metastatic renal cell carcinoma: a European multicentre phase II study. Eur J Cancer. 1991 Dec; 27: 1583–9

    Article  PubMed  Google Scholar 

  8. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995 Mar; 13: 688–96

    PubMed  CAS  Google Scholar 

  9. Edwards RP, Gooding W, Lembersky BC, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 1997 Nov; 15: 3399–407

    PubMed  CAS  Google Scholar 

  10. Davey Jr RT, Chaitt DG, Albert JM, et al. Arandomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999 Apr; 179: 849–58

    Article  PubMed  CAS  Google Scholar 

  11. World Health Organization. Closer cooperation the way to better health — Gro Harlem Brundtland [press release]. World Health Organization [online], 18 May 1999. Available from URL: http://www.who.int [Accessed on 1999 Oct 5]

  12. Pardo M, Castillo I, Oliva H, et al. Apilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. Hepatology 1997 Nov; 26: 1318–21

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aldesleukin. Drugs R&D 2, 267–270 (1999). https://doi.org/10.2165/00126839-199902040-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902040-00012

Keywords

Search

Navigation